CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Revenue, Net (Deprecated 2018-01-31)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Revenue, Net (Deprecated 2018-01-31) of $1.86 billion for the 12-month period ending 2017-12-30, per its 10-K filed 2018-02-13.
Discontinued › Income Statement › Revenue
us-gaap:SalesRevenueNet · last filed 2018-02-13
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. revenue, net (deprecated 2018-01-31) for the quarter ending 2014-06-28 was $341.18M, a 16.47% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. revenue, net (deprecated 2018-01-31) for the quarter ending 2014-03-29 was $299.37M, a 2.79% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. revenue, net (deprecated 2018-01-31) for the quarter ending 2013-12-28 was $289.23M, a 3.24% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. revenue, net (deprecated 2018-01-31) for the quarter ending 2013-09-28 was $292.13M, a 4.82% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. revenue, net (deprecated 2018-01-31) for fiscal 2017 was $1.86B, a 10.48% increase from fiscal 2016.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. revenue, net (deprecated 2018-01-31) for fiscal 2016 was $1.68B, a 23.34% increase from fiscal 2015.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. revenue, net (deprecated 2018-01-31) for fiscal 2015 was $1.36B, a 5.06% increase from fiscal 2014.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. revenue, net (deprecated 2018-01-31) for fiscal 2014 was $1.30B, a 11.34% increase from fiscal 2013.
| Period end | Revenue, Net (Deprecated 2018-01-31) 3 month | Revenue, Net (Deprecated 2018-01-31) 3 month as first filed | Revenue, Net (Deprecated 2018-01-31) 6 month | Revenue, Net (Deprecated 2018-01-31) 6 month as first filed | Revenue, Net (Deprecated 2018-01-31) 9 month | Revenue, Net (Deprecated 2018-01-31) 9 month as first filed | Revenue, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|---|---|---|
| 2017-12-30 | $1.86B 10-K · filed 2018-02-13 | ||||||
| 2016-12-31 | $1.68B 10-K · filed 2018-02-13 | ||||||
| 2015-12-26 | $1.36B 10-K · filed 2018-02-13 | ||||||
| 2014-12-27 | $1.30B 10-K · filed 2017-02-14 | ||||||
| 2014-06-28 | $341.18M 10-Q · filed 2014-08-07 | $640.55M 10-Q · filed 2014-08-07 | $929.77M derived: sum of 3 quarters · filed 2016-02-12 | $1.22B derived: sum of 4 quarters · filed 2016-02-12 | |||
| 2014-03-29 | $299.37M 10-Q · filed 2014-04-30 | $588.60M derived: sum of 2 quarters · filed 2016-02-12 | $880.73M derived: sum of 3 quarters · filed 2016-02-12 | $1.17B derived: sum of 4 quarters · filed 2016-02-12 | |||
| 2013-12-28 | $289.23M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $581.36M derived: sum of 2 quarters · filed 2016-02-12 | $874.29M derived: sum of 3 quarters · filed 2016-02-12 | $1.17B 10-K · filed 2016-02-12 | |||
| 2013-09-28 | $292.13M 10-Q · filed 2013-10-30 | $585.06M derived: sum of 2 quarters · filed 2014-08-07 | $876.30M 10-Q · filed 2013-10-30 | $1.16B derived: sum of 4 quarters · filed 2015-02-17 | |||
| 2013-06-29 | $292.93M 10-Q · filed 2014-08-07 | $584.17M 10-Q · filed 2014-08-07 | $864.31M derived: sum of 3 quarters · filed 2015-02-17 | $1.14B derived: sum of 4 quarters · filed 2015-02-17 | |||
| 2013-03-30 | $291.24M 10-Q · filed 2014-04-30 | $571.38M derived: sum of 2 quarters · filed 2015-02-17 | $850.06M derived: sum of 3 quarters · filed 2015-02-17 | $1.13B derived: sum of 4 quarters · filed 2015-02-17 | |||
| 2012-12-29 | $280.14M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-17 | $558.83M derived: sum of 2 quarters · filed 2015-02-17 | $843.55M derived: sum of 3 quarters · filed 2015-02-17 | $1.13B 10-K · filed 2015-02-17 | |||
| 2012-09-29 | $278.69M 10-Q · filed 2013-10-30 | $563.41M derived: sum of 2 quarters · filed 2013-10-30 | $849.39M 10-Q · filed 2013-10-30 | $1.14B derived: sum of 4 quarters · filed 2014-02-25 | |||
| 2012-06-30 | $284.72M 10-Q · filed 2013-07-31 | $570.70M 10-Q · filed 2013-07-31 | $861.67M derived: sum of 3 quarters · filed 2014-02-25 | $1.14B derived: sum of 4 quarters · filed 2014-02-25 | |||
| 2012-03-31 | $285.98M 10-Q · filed 2013-05-08 | $576.94M derived: sum of 2 quarters · filed 2014-02-25 | $854.52M derived: sum of 3 quarters · filed 2014-02-25 | $1.14B derived: sum of 4 quarters · filed 2014-02-25 | |||
| 2011-12-31 | $290.96M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $568.54M derived: sum of 2 quarters · filed 2014-02-25 | $856.80M derived: sum of 3 quarters · filed 2014-02-25 | $1.14B 10-K · filed 2014-02-25 | |||
| 2011-09-24 | $277.58M 10-Q · filed 2012-11-01 | $565.84M derived: sum of 2 quarters · filed 2012-11-01 | $851.68M 10-Q · filed 2012-11-01 | $1.13B derived: sum of 4 quarters · filed 2013-02-27 | |||
| 2011-06-25 | $288.26M 10-Q · filed 2012-08-07 | $574.11M 10-Q · filed 2012-08-07 | $855.76M derived: sum of 3 quarters · filed 2013-02-27 | $1.13B derived: sum of 4 quarters · filed 2013-02-27 | |||
| 2011-03-26 | $285.84M 10-Q · filed 2012-05-04 | $567.50M derived: sum of 2 quarters · filed 2013-02-27 | $838.38M derived: sum of 3 quarters · filed 2013-02-27 | $1.13B derived: sum of 4 quarters · filed 2013-02-27 | |||
| 2010-12-25 | $281.65M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $552.54M derived: sum of 2 quarters · filed 2013-02-27 | $841.13M derived: sum of 3 quarters · filed 2013-02-27 | $1.13B 10-K · filed 2013-02-27 | |||
| 2010-09-25 | $270.88M 10-Q · filed 2011-11-02 | $276.08M 10-Q · filed 2010-11-04 | $559.48M derived: sum of 2 quarters · filed 2011-11-02 | $851.76M 10-Q · filed 2011-11-02 | $865.53M 10-Q · filed 2010-11-04 | $1.12B derived: sum of 4 quarters · filed 2012-02-27 | |
| 2010-06-26 | $288.59M 10-Q · filed 2011-08-03 | $292.10M 10-Q · filed 2010-08-03 | $580.88M 10-Q · filed 2011-08-03 | $589.45M 10-Q · filed 2010-08-03 | $845.35M derived: sum of 3 quarters · filed 2012-02-27 | $1.14B derived: sum of 4 quarters · filed 2012-02-27 | |
| 2010-03-27 | $292.29M 10-Q · filed 2011-05-04 | $556.76M derived: sum of 2 quarters · filed 2012-02-27 | $854.24M derived: sum of 3 quarters · filed 2012-02-27 | $1.16B derived: sum of 4 quarters · filed 2012-02-27 | |||
| 2009-12-26 | $264.47M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-27 | $561.96M derived: sum of 2 quarters · filed 2012-02-27 | $870.12M derived: sum of 3 quarters · filed 2012-02-27 | $1.17B 10-K · filed 2012-02-27 | |||
| 2009-09-26 | $297.49M 10-Q · filed 2010-11-04 | $605.64M derived: sum of 2 quarters · filed 2010-11-04 | $907.17M 10-Q · filed 2010-11-04 | ||||
| 2009-06-27 | $308.16M 10-Q · filed 2010-08-03 | $609.68M 10-Q · filed 2010-08-03 | |||||
| 2008-12-27 | $1.30B 10-K · filed 2011-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |